Rivaroxaban is an oral , direct Factor Xa inhibitor , approved for the treatment of pulmonary embolism ( PE ) and deep vein thrombosis ( DVT ) and the secondary prevention of recurrent PE and DVT as a fixed-dose , monotherapy regimen that does not require initial heparinisation , routine coagulation monitoring or dose adjustment .